(Q34807704)

English

A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer (English)

1 reference

Europe PubMed Central

4 August 2017

chemoradiotherapy

0 references

1 reference

based on heuristic

inferred from title

16

object named as

Rakesh K Jain

1 reference

Europe PubMed Central

4 August 2017

4

object named as

Mira Shah

1 reference

Europe PubMed Central

4 August 2017

13

object named as

Paul Shellito

1 reference

Europe PubMed Central

4 August 2017

Christopher Mantyh

12

object named as

Christopher Mantyh

1 reference

Europe PubMed Central

4 August 2017

Marek Ancukiewicz

3

object named as

Marek Ancukiewicz

1 reference

Europe PubMed Central

4 August 2017

author name string

Christopher G Willett

1

1 reference

Europe PubMed Central

4 August 2017

Dan G Duda

2

1 reference

Europe PubMed Central

4 August 2017

Brian G Czito

5

1 reference

Europe PubMed Central

4 August 2017

Rex Bentley

6

1 reference

Europe PubMed Central

4 August 2017

Martin Poleski

7

1 reference

Europe PubMed Central

4 August 2017

Hiroshi Fujita

8

1 reference

Europe PubMed Central

4 August 2017

Gregory Y Lauwers

9

1 reference

Europe PubMed Central

4 August 2017

Madeline Carroll

10

1 reference

Europe PubMed Central

4 August 2017

Douglas Tyler

11

1 reference

Europe PubMed Central

4 August 2017

Daniel C Chung

14

1 reference

Europe PubMed Central

4 August 2017

Jeffrey W Clark

15

1 reference

Europe PubMed Central

4 August 2017

publication date

28 July 2010

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

15

1 reference

Europe PubMed Central

4 August 2017

845-851

1 reference

Europe PubMed Central

4 August 2017

8

1 reference

Europe PubMed Central

4 August 2017

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Preoperative versus postoperative chemoradiotherapy for rectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

The biology of VEGF and its receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

8 July 2018

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

26 October 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078712

9 December 2018

Identifiers

10.1634/THEONCOLOGIST.2010-0030

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34807704&oldid=2114037447"